ARATANA THERAPEUTICS, INC.
DelistedCIK 1509190fmd_0NK1C0ZQ6TJV29M485KQZHZYBMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Mar 31, 2019, 30 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 1 | 1 | 39 | 26 | 35 |
| Cost of revenue | – | – | 0 | 0 | 0 | 3 | 16 | 7 |
| Gross profit | – | – | 0 | 0 | 0 | 35 | 9 | 29 |
| Research and development | 2 | 7 | 11 | 20 | 25 | 30 | 15 | 7 |
| Selling, general and administrative | – | 3 | 9 | 18 | 20 | 27 | 29 | 29 |
| Operating income | (3) | (12) | (20) | (42) | (89) | (31) | (44) | (12) |
| Interest expense | – | – | 0 | 1 | 2 | 3 | 3 | 3 |
| Other non-operating income (expense) | 0 | 0 | 0 | 1 | 4 | (3) | (3) | (3) |
| Income before taxes | (3) | (12) | (20) | (40) | (86) | (34) | (48) | (15) |
| Income tax expense | – | – | (13) | (1) | (2) | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (7) | (39) | (84) | (34) | (48) | (15) |
| Net income | (3) | (12) | (7) | (39) | (84) | (34) | (48) | (15) |
| Net income to common shareholders | (5) | (14) | (7) | (39) | – | – | – | – |